<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128973</url>
  </required_header>
  <id_info>
    <org_study_id>050213</org_study_id>
    <secondary_id>05-I-0213</secondary_id>
    <nct_id>NCT00128973</nct_id>
  </id_info>
  <brief_title>Evaluation of Patients With Immune Function Abnormalities</brief_title>
  <official_title>Screening and Baseline Assessment of Patients With Abnormalities of Immune Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will evaluate patients with abnormal immune function that results in recurrent or&#xD;
      unusual infections or chronic inflammation. This may include inherited conditions, such as&#xD;
      X-linked severe combined immunodeficiency (XSCID), chronic granulomatous disease (CGD), and&#xD;
      leukocyte adhesion deficiency (LAD), or conditions resulting from outside factors, such as&#xD;
      graft-versus-host disease (GVHD). The information from this study will be used to establish&#xD;
      the pattern and pace of change of the disease and to help develop new treatments. The period&#xD;
      of observation and study following enrollment in this study may be for up to one year. In&#xD;
      addition these studies may provide the medical information needed to determine eligibility&#xD;
      for enrollment in other clinical study protocols and more prolonged follow up.&#xD;
&#xD;
      Patients of any age with abnormal immune function who have recurrent or unusual infections,&#xD;
      whose blood tests show evidence of immune dysfunction, or who have GVHD, XSCID, CGD or LAD&#xD;
      may be eligible for this study. Patients' parents, siblings, grandparents, children, aunts,&#xD;
      uncles and first cousins of any age also may be included. Healthy normal volunteers between&#xD;
      18 and 85 years of age are recruited as controls.&#xD;
&#xD;
      Normal volunteers undergo a physical examination and provide blood, saliva, and urine samples&#xD;
      for immune function studies. Patients' family members provide a medical history, have a&#xD;
      physical examination, and give blood and urine samples, and possibly a saliva sample. The&#xD;
      samples are used for genetic and routine laboratory studies. Investigators may request tissue&#xD;
      samples, such as biopsy specimens, previously removed for medical reasons to be sent to NIH&#xD;
      for study. Patients undergo the following tests and procedures:&#xD;
&#xD;
        1. Medical history and physical examination.&#xD;
&#xD;
        2. Blood and urine tests, including analysis for genes involved in immune disorders.&#xD;
&#xD;
        3. Buccal smear (in some patients) for genetic studies. This involves scraping the lining&#xD;
           of the mouth near the cheek.&#xD;
&#xD;
        4. Specialized tests to evaluate specific conditions in patients who have an immune&#xD;
           disorder that might affect lung function, gum infections or eye problems. These may&#xD;
           include chest x-ray, CT scan, breathing function test, dental, eye, and hearing&#xD;
           examinations.&#xD;
&#xD;
        5. Follow-up visits of patients with immune problems may occur at 6 months and at one year&#xD;
           after the first visit (or more frequently if medically required) to include:&#xD;
&#xD;
             -  Medical history update&#xD;
&#xD;
             -  Physical examination&#xD;
&#xD;
             -  Follow-up on abnormal test results and medical treatments initiated at NIH&#xD;
&#xD;
             -  Collection of blood, saliva, urine, or wound drainage samples for repeat immune&#xD;
                function studies&#xD;
&#xD;
             -  Tissue study of specimens removed for medical reasons at other institutions besides&#xD;
                NIH&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol is designed for the screening and baseline assessment of and collection of&#xD;
      research sample from patients with abnormalities of immune function as manifested by&#xD;
      recurrent or unusual infections, recurrent or chronic inflammation, or previous laboratory&#xD;
      evidence of immune dysfunction. Abnormalities of immune function may be inherited or may be&#xD;
      iatrogenic such as that following hematopoietic stem cell transplantation or other treatments&#xD;
      resulting in prolonged immune dysfunction. Blood and/or bone marrow cells may also be used to&#xD;
      investigate the utility of induced pluripotent stem cells (iPS) for immune cell derivation&#xD;
      and targeted gene correction. This is not a protocol to study or screen for human&#xD;
      immunodeficiency virus infection, though patients with HIV infection who may have other&#xD;
      causes for immune dysfunction are not excluded. First or second degree genetically related&#xD;
      family members (limited to mother, father, siblings, grandparents, children, aunts, uncles&#xD;
      and first cousins of an affected patient) may also be screened for clinical, in vitro and&#xD;
      genetic correlates of immune abnormalities. Healthy Volunteers will be enrolled as a source&#xD;
      of control blood samples for research testing, not to include genetic testing. Screening and&#xD;
      baseline assessment under the auspices of this study may be limited to two visits over one&#xD;
      year period, unless the patient has been determined by initial evaluation to require further&#xD;
      study at NIH or are ongoing long-term safety assessments as required by their participation&#xD;
      on a gene therapy or transplant protocol. Patients with documented immune dysfunction may&#xD;
      receive limited medically indicated treatment if that medically indicated treatment is&#xD;
      related to the abnormality of immune function under study, with such treatment limited to the&#xD;
      period of the one year baseline assessment indicated in this protocol. When screening and&#xD;
      assessment is complete, patients will be offered an opportunity to participate in another&#xD;
      study, or if there are no active studies appropriate for the patient, other options will be&#xD;
      suggested to the primary or referring physician.&#xD;
&#xD;
      This protocol will allow detailed investigation of patients with abnormalities of immune&#xD;
      function with up to one year of observation with the following goals:&#xD;
&#xD;
        1. To determine the degree, scope and cause of immune dysfunction;&#xD;
&#xD;
        2. To establish the pace and pattern of change in the disease process;&#xD;
&#xD;
        3. To determine the extent of organ involvement and damage from immune dysfunction.&#xD;
&#xD;
      This screening and baseline assessment is necessary to discover new causes of immune&#xD;
      abnormalities, to delineate epidemiology of immune deficiencies, to develop new diagnostic&#xD;
      and therapeutic tools, and to determine a patient's eligibility for other studies.&#xD;
&#xD;
      Lung MRI as a CT supplement in Infection Surveillance in Immunodeficiencies:&#xD;
&#xD;
      The routine use of computed tomography (CT) has increased substantially since its&#xD;
      introduction into medicine, which, in turn, has also increased the amount of radiation to&#xD;
      which individuals are exposed. This increased radiation is not without risk and is&#xD;
      particularly problematic in our primary immunodeficiency disease population, who require&#xD;
      serial imaging with chest CTs to manage pneumonia. Standard medical practice in this patient&#xD;
      population is to diagnose infection by obtaining a diagnostic CT and then repeating the CT&#xD;
      every three to four weeks until the lesion has resolved in order to guide the treatment&#xD;
      course.&#xD;
&#xD;
      Although the radiation dose at our institution has been reduced by a factor of four in the&#xD;
      last several years as a result of peak kilovoltage (kVp) reduction dose modulation and&#xD;
      iterative reconstruction; cumulative radiation exposure carries an increased lifetime risk&#xD;
      for cancer and reducing exposure should be in keeping with the mandate, As Low As Reasonably&#xD;
      Achievable (ALARA).&#xD;
&#xD;
      Magnetic resonance imaging (MRI), which does not expose the patient to any ionizing&#xD;
      radiation, has shown promise in detecting the obvious infiltrates secondary to cross&#xD;
      sectional ability and increasing resolution.&#xD;
&#xD;
      Previously, lung MRI had not been considered as a potential substitute for CT because of poor&#xD;
      signal- to- noise ratio (SNR) due to the low density of protons in lung parenchyma, the short&#xD;
      T2* relaxation time in the lungs secondary to air-tissue based susceptibility, and the&#xD;
      challenge of imaging over long scan times resulting in respiratory, vascular and cardiac&#xD;
      motion artifacts.&#xD;
&#xD;
      However, the recent development of MRI scanning techniques that provide an ultra short echo&#xD;
      time (UTE) along with oversampling of k-space center appear to overcome the above mentioned&#xD;
      drawbacks of MRI for imaging the lung/ chest.&#xD;
&#xD;
      For this protocol, we will use optimized versions of the MRI UTE pulse sequence on our 3T&#xD;
      clinical scanners to perform breath-hold (BH) coronal and BH and free-breathing axial images.&#xD;
      Our goal is to comprehensively evaluate the lung without additional radiation with a&#xD;
      clinically reasonable scan time of &lt;30 minutes, especially with a proportionally high&#xD;
      percentage of young adults.&#xD;
&#xD;
      Subjects enrolled under 05-I-0213 with primary immune deficiencies may be considered for&#xD;
      participation in the sub study to evaluate the feasibility of novel MRI techniques compared&#xD;
      with standard CT imaging for pathology surveillance if they are undergoing medically&#xD;
      indicated CT imaging for the diagnosis or monitoring of infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2005</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the physiologic, biochemical or genetic basis of the abnormality of immunity.</measure>
    <time_frame>ongoing throughout study</time_frame>
    <description>Identification of the pathophysiology and genetic basis of abnormalities of immune function under study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To establish the extent of organ involvement (infection and/or inflammation) and organ damage or dysfunction resulting from the abnormality of immune function.</measure>
    <time_frame>ongoing throughout study</time_frame>
    <description>Identification of severity of disease as it relates to immune function in PID</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To establish the pattern and pace of change of disease (frequency, distribution, type and extent of infections, inflammatory lesions and abnormalities of immune function) during a period of up</measure>
    <time_frame>ongoing throughout study</time_frame>
    <description>Identification pregression and pattern of disease over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine genetic linkage and biochemical correlates of the patient's abnormality of immunity by study of first and second-degree related family members' blood cells (buccal smears instead of blood for genetic studies in some individuals), se...</measure>
    <time_frame>ongoing throughout study</time_frame>
    <description>Identification of genetic links and biochemical correlates of PID to clinical manifestations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine a patient's eligibility for other studies.</measure>
    <time_frame>ongoing throughout study</time_frame>
    <description>Patient recruitment to treatment protocols</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the patient's ability to safely tolerate specific aspects of other diagnostic or therapeutic research protocols.</measure>
    <time_frame>ongoing throughout study</time_frame>
    <description>Patients tolerate treatment for PID disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To establish a baseline assessment of the pace and extent of the disease before entering a therapeutic clinical trial.</measure>
    <time_frame>ongoing throughout study</time_frame>
    <description>Identification of best time with respect to disease process to place pts on a treatment protocol</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Chronic Granulomatous Disease (CGD)</condition>
  <condition>X-Linked Severe Combined Immune Deficiency (XSCID)</condition>
  <condition>Leukocyte Adhesion Deficiency 1 (LAD)</condition>
  <condition>Graft Versus Host Disease (cGvHD)</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <description>Healthy adult M/F 18-85 y/o.Hgb greater than or equal to 11. Wt&gt;110 bs. No heart, lung, kidney, bleeding disorders. No hep BorC since age ll. No IV drug use. No exposure to the AIDS virus. Not pregnant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients with abnormalities of immune function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relatives of Patients</arm_group_label>
    <description>Relatives may be mother, father, siblings, children, grandparents, aunts, uncles, and first cousins to a patient.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Self referred, Physician referred&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Patients:&#xD;
&#xD;
          -  Patients with abnormalities of immune function as manifested by recurrent or unusual&#xD;
             infections, recurrent or chronic inflammation, or previous laboratory evidence of&#xD;
             immune dysfunction are eligible for screening and baseline assessment under this&#xD;
             protocol.&#xD;
&#xD;
          -  Of particular focus of this study are patients with clinical features or medical&#xD;
             history suggestive of Chronic Granulomatous Disease (CGD), X-linked Severe Combined&#xD;
             Immune Deficiency (XSCID), Leukocyte Adhesion Deficiency 1 (LAD) or chronic Graft&#xD;
             versus Host Disease (cGvHD).&#xD;
&#xD;
          -  There will be no limit due to age, sex, race, or disability.&#xD;
&#xD;
          -  All patients must have a primary physician outside of the NIH.&#xD;
&#xD;
          -  Women of child-bearing potential, or who are pregnant or lactating, may be eligible&#xD;
             and will only undergo tests and procedures, and/or receive medications for which data&#xD;
             exists proven minimal risk to the fetus or child. Only diagnostic tests without&#xD;
             radiographs will be performed.&#xD;
&#xD;
          -  All patients will be required to have blood stored for future studies (such as but not&#xD;
             limited to the modification of cells into iPS cells), and/or other medical conditions.&#xD;
&#xD;
        Relatives of Patient:&#xD;
&#xD;
          -  Relatives may be mother, father, siblings, children, grandparents, aunts, uncles, and&#xD;
             first cousins to a patient.&#xD;
&#xD;
          -  There is no limit due to age, sex, race or disability.&#xD;
&#xD;
          -  Women of childbearing potential, or who are pregnant or lactating, may be eligible and&#xD;
             will only undergo tests and procedures, and/or receive medications for which data&#xD;
             exists proven minimal risk to the fetus or child. Pregnant females will undergo&#xD;
             diagnostic tests without radiograph exposure.&#xD;
&#xD;
          -  Must be willing to have blood stored for future studies and/or other research&#xD;
             purposes.&#xD;
&#xD;
        Healthy Volunteers must:&#xD;
&#xD;
          -  Be a healthy adult of either sex and between age of 18 and 85 years old.&#xD;
&#xD;
          -  Have a hemoglobin count of greater than or equal to 11.&#xD;
&#xD;
          -  Weight greater than 110 pounds.&#xD;
&#xD;
          -  Not have any heart, lung, or kidney disease, or bleeding disorders.&#xD;
&#xD;
          -  Not have a history of viral hepatitis (B or C) since age 11.&#xD;
&#xD;
          -  Not have a history of intravenous injection drug use.&#xD;
&#xD;
          -  Not have a history of engaging in high-risk activities for exposure to the AIDS virus.&#xD;
&#xD;
          -  Not be pregnant&#xD;
&#xD;
          -  Be willing to have their blood samples stored for future research and modified iPS&#xD;
             cells.&#xD;
&#xD;
        Patient Participants in the FDG PET-CT and/or FDG PET-CT/MR-PET Scan Study Must:&#xD;
&#xD;
        - Already be enrolled and eligible to participate on protocol #05-I-0213 Screening and&#xD;
        Baseline Assessment of Patients with&#xD;
&#xD;
        Abnormalities of Immune Function&#xD;
&#xD;
        - Be at least 8 years old&#xD;
&#xD;
        Must have clinical evidence for significant life-threatening infection that would be a&#xD;
        standard of care medical indication for diagnostic CT scan where the FDG PET-CT/MR-PET scan&#xD;
        would be performed in lieu of that indicated diagnostic CT; or have had a CT or MRI that&#xD;
        did not adequately indicate the anatomic extent, location(s) or intensity of the infection&#xD;
&#xD;
          -  Must be capable of overnight fasting and stopping of any intravenous glucose or other&#xD;
             intravenous nutritional feeding for at least 12 hours before the FDG injection and&#xD;
             through the period of time required for the FDG PET-CT/MR-PET scans, because glucose&#xD;
             and insulin significantly inhibits uptake of FDG.&#xD;
&#xD;
          -  Must be psychologically capable of remaining in the confined space of the PET-CT and&#xD;
             MR-PET instruments. Patient will remain eligible for FDG PET-CT alone if the subject&#xD;
             cannot tolerate the confines of the MR-PET instrument.&#xD;
&#xD;
        Patient Participants in Lung MRI as a CT supplement in Infection Surveillance Sub Study&#xD;
        Must:&#xD;
&#xD;
          -  Have a primary immune deficiency and be enrolled under 05-I-0213.&#xD;
&#xD;
          -  Be willing to sign a supplemental consent to undergo lung MRI.&#xD;
&#xD;
          -  Be greater or equal to 12 years of age&#xD;
&#xD;
          -  Need a medically indicated chest CT&#xD;
&#xD;
          -  Be psychologically/physically capable of remaining in the confined space of the MRI&#xD;
             machine for at least 30 minutes.&#xD;
&#xD;
          -  Be able to lay flat.&#xD;
&#xD;
          -  Be capable of following breath-holding instructions.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Patients:&#xD;
&#xD;
          -  The presence of certain types of acquired abnormalities of immunity solely due to HIV,&#xD;
             chemotherapeutic agent(s), or an underlying malignancy could be grounds for possible&#xD;
             exclusion for a patient.&#xD;
&#xD;
          -  In the opinion of the investigator, the presence of such disease processes may&#xD;
             interfere with the evaluation of a co-existing abnormality of immunity that is the&#xD;
             subject of study under this protocol.&#xD;
&#xD;
          -  Pregnant women will not be allowed to participate in any procedure that may be&#xD;
             dangerous to the pregnancy or the fetus, such as risk of radiographic studies.&#xD;
&#xD;
        Relatives of Patient:&#xD;
&#xD;
          -  The presence of certain types of acquired abnormalities of immunity solely due to HIV,&#xD;
             chemotherapeutic agent(s), or an underlying malignancy could be grounds for possible&#xD;
             exclusion for a relative.&#xD;
&#xD;
          -  In the opinion of the investigator, the presence of such disease processes may&#xD;
             interfere with evaluation of a co-existing abnormality of immunity that is the subject&#xD;
             of study under this protocol.&#xD;
&#xD;
          -  Pregnant female relatives will not be allowed to participate in any procedure that may&#xD;
             be dangerous to the pregnancy or the fetus.&#xD;
&#xD;
        Healthy Volunteer not eligible if:&#xD;
&#xD;
          -  Less than 18 years old or older than 85 years.&#xD;
&#xD;
          -  Have viral hepatitis (B or C).&#xD;
&#xD;
          -  Receiving chemotherapeutic agent(s) or have underlying malignancy.&#xD;
&#xD;
          -  Pregnant.&#xD;
&#xD;
          -  Have history of heart, lung, kidney disease, or bleeding disorders.&#xD;
&#xD;
        Patient Participants in the FDG PET-CT and/or FDG PET-CT/MRPET Scan Study Must Not:&#xD;
&#xD;
          -  Have cancer or have had radiation or chemotherapy to treat a cancer in the past 5&#xD;
             years.&#xD;
&#xD;
          -  Have diabetes or abnormal glucose tolerance.&#xD;
&#xD;
          -  Weigh more than 299lbs (or 136kg) or cannot fit in the bore of the instruments.&#xD;
&#xD;
          -  Are a women of childbearing potential, you must have a negative urine or blood&#xD;
             pregnancy test within 1days prior to having the FDG&#xD;
&#xD;
        PET-CT/MR-PET scans.&#xD;
&#xD;
        - If you have aneurysm clips, metal fragments in the eye, certain types of metal implants&#xD;
        or prostheses, a pacemaker or other permanently attached electronic devices that are not&#xD;
        marked MRI compatible you may not be able to participate in the MR-PET portion of the study&#xD;
&#xD;
        Patient Participants in Lung MRI as a CT supplement in Infection Surveillance Sub Study&#xD;
        Must Not:&#xD;
&#xD;
          -  Be less than 12 years of age&#xD;
&#xD;
          -  Have claustrophobia or require sedation to undergo an MRI.&#xD;
&#xD;
          -  Have an implanted metal object in the body (i.e. aneurysm clips, metal fragments in&#xD;
             the eye) that is contraindicated for MRI.&#xD;
&#xD;
          -  Be pregnant.&#xD;
&#xD;
          -  Have a body habitus greater than MRI gantry size/weight limit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry L Malech, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia L Littel, R.N.</last_name>
    <phone>(301) 335-1744</phone>
    <email>plittel@mail.nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harry L Malech, M.D.</last_name>
    <phone>(301) 480-6916</phone>
    <email>hmalech@nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2005-I-0213.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, McBride OW, Leonard WJ. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993 Apr 9;73(1):147-57.</citation>
    <PMID>8462096</PMID>
  </reference>
  <reference>
    <citation>Puck JM, DeschÃªnes SM, Porter JC, Dutra AS, Brown CJ, Willard HF, Henthorn PS. The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1. Hum Mol Genet. 1993 Aug;2(8):1099-104.</citation>
    <PMID>8401490</PMID>
  </reference>
  <reference>
    <citation>Stephan JL, Vlekova V, Le Deist F, Blanche S, Donadieu J, De Saint-Basile G, Durandy A, Griscelli C, Fischer A. Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J Pediatr. 1993 Oct;123(4):564-72.</citation>
    <PMID>8410508</PMID>
  </reference>
  <verification_date>April 21, 2021</verification_date>
  <study_first_submitted>August 9, 2005</study_first_submitted>
  <study_first_submitted_qc>August 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2005</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infection</keyword>
  <keyword>Genetic</keyword>
  <keyword>Inherited Disease</keyword>
  <keyword>Immunity</keyword>
  <keyword>Chronic</keyword>
  <keyword>Abnormal Immune Function</keyword>
  <keyword>Recurrent Infection</keyword>
  <keyword>Chronic Granulomatous Disease</keyword>
  <keyword>CGD</keyword>
  <keyword>X-Linked Severe Combined Immune Deficiency (XSCID)</keyword>
  <keyword>XSCID</keyword>
  <keyword>Leukocyte Adhesion Deficiency 1</keyword>
  <keyword>LAD</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>HV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granulomatous Disease, Chronic</mesh_term>
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

